dailyloe.com – Novo Nordisk’s new oral weight loss drug, Wegovy, is rapidly expanding the obesity treatment market by attracting new patients. The pill launched in early January and has seen explosive prescription demand. Early data suggests it is pulling in people who previously avoided injectable GLP-1 therapies.
Many new patients share common barriers to earlier treatment. These include high out-of-pocket costs for injections or a significant fear of needles. The oral format is removing a key obstacle to starting medication.
Jane Zuckerman, a 32-year-old data analyst, is one such patient. She had tried traditional weight loss methods for years without lasting success. The availability of a pill prompted her to call her doctor immediately.
Zuckerman reported losing around 11 pounds in her first month on the medication. She had previously lost 90 pounds in college but regained weight post-pandemic. Injectable GLP-1s were not an option due to her needle phobia.
CNBC spoke with five U.S. patients who recently started the pill. All five confirmed they had never taken branded GLP-1 injections before. Their experiences highlight a trend of market expansion rather than patient conversion.
It remains early days for the oral Wegovy treatment. Many patients have not yet reached the drug’s higher, more effective doses. Individual experiences with the pill are also varying widely at this stage.
The long-term effectiveness of the pill is still being evaluated. Key questions remain about sustained weight loss and patient adherence. Comparisons to injectable therapies on these metrics will take more time.
Novo Nordisk’s product also faces upcoming market competition. Rival pharmaceutical company Eli Lilly is expected to launch competing treatments. It is unclear if the current demand surge will be sustained.
The early rollout indicates a significant shift in patient access. An oral option is making obesity pharmacotherapy available to a broader demographic. This could substantially increase the total number of people receiving medical weight management.[]
Source: CNBC
